| Valerie W Peckingham, PT | |
|
863 N Main Street Ext Ste 200, Wallingford, CT 06492-2434 | |
| (203) 265-3280 | |
| Not Available |
| Full Name | Valerie W Peckingham |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 32 Years |
| Location | 863 N Main Street Ext Ste 200, Wallingford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568580132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 004902 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Orthopedics And Musculoskeletal Care Llc | 9830097864 | 19 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
The Neuroendocrine Tumor Research Foundation continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million.
Although people can seek exemptions from this requirement to buy coverage, only about 77,000 have done so, The Washington Post reports. Meanwhile, payment issues are also in the headlines as KHN looks at insurers' efforts to set the 2015 rates for policies on the health law's marketplaces, and the New York Times examines a panel's findings about the law's effects on doctors and hospitals treating many poor patients.
› Verified 6 days ago
| Entity Name | Comprehensive Orthopedics & Musculoskeletal Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790844330 PECOS PAC ID: 9830097864 Enrollment ID: O20031229000526 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
The Neuroendocrine Tumor Research Foundation continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million.
Although people can seek exemptions from this requirement to buy coverage, only about 77,000 have done so, The Washington Post reports. Meanwhile, payment issues are also in the headlines as KHN looks at insurers' efforts to set the 2015 rates for policies on the health law's marketplaces, and the New York Times examines a panel's findings about the law's effects on doctors and hospitals treating many poor patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Valerie W Peckingham, PT 863 N Main Street Ext Ste 200, Wallingford, CT 06492-2434 Ph: (203) 265-3280 | Valerie W Peckingham, PT 863 N Main Street Ext Ste 200, Wallingford, CT 06492-2434 Ph: (203) 265-3280 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
The Neuroendocrine Tumor Research Foundation continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million.
Although people can seek exemptions from this requirement to buy coverage, only about 77,000 have done so, The Washington Post reports. Meanwhile, payment issues are also in the headlines as KHN looks at insurers' efforts to set the 2015 rates for policies on the health law's marketplaces, and the New York Times examines a panel's findings about the law's effects on doctors and hospitals treating many poor patients.
› Verified 6 days ago
Paul Acampora, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Northrop Rd, Wallingford, CT 06492 Phone: 203-949-1534 Fax: 203-949-9036 | |
Kathryn M Papadikis, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Northrop Rd, Wallingford, CT 06492 Phone: 615-778-4066 |